ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday, July 18th.
According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “
A number of other equities analysts have also recently issued reports on EPIX. Bloom Burton reiterated a “buy” rating on shares of ESSA Pharma in a report on Thursday, May 18th. ValuEngine lowered ESSA Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 7th.
Shares of ESSA Pharma (EPIX) traded up 5.13% during mid-day trading on Tuesday, reaching $0.41. The company had a trading volume of 29,920 shares. The firm’s 50-day moving average price is $0.49 and its 200 day moving average price is $1.79. The company’s market cap is $11.93 million. ESSA Pharma has a 52-week low of $0.25 and a 52-week high of $3.59.
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
